Introduction {#S1}
============

HIV-infected patients have a lower ability to induce and maintain an effective response to routine vaccinations due to the depletion of central memory CD4 T cells, particularly T follicular helper cells, and perturbation of the B cell compartment with reduced resting memory (RM) B cells ([@B1]--[@B4]). Antiretroviral therapy (ART) can restore the quantitative loss of RM B cells in HIV-infected children ([@B5], [@B6]). However, a suboptimal antibody response against infection and vaccination may persist, suggesting a qualitative impairment of B cells. Indeed, a sizeable proportion of HIV-infected children require booster immunizations to provide adequate protection usually achieved by routine vaccinations in healthy children ([@B7]--[@B9]). Additionally, children with apparently similar clinical and immunological characteristics can vary in adequacy of responsiveness to infection and/or vaccination bringing into question host factors that are critical for mounting an immune response ([@B10], [@B11]). The molecular correlates governing effective and long lasting immune responses are still unknown ([@B4], [@B12]--[@B14]). In recent years, systems biology and vaccinomics approaches have attempted to dissect vaccine-induced responses in humans ([@B15]--[@B19]). For influenza, gene expression and robustness of response have been found to differ upon vaccination with trivalent-inactivated influenza vaccination (TIV) as compared to live attenuated influenza vaccine ([@B20]). In addition, advanced "omics" and systems biology approaches have led to increased knowledge regarding molecular mechanisms underlying adaptive immune responses to different types of vaccines ([@B21], [@B22]). In most instances however, these data have been derived from RNA extracted from whole blood or from the heterogeneous pool of peripheral blood mononuclear cells (PBMCs) of healthy volunteers ([@B18], [@B23]), thereby limiting interpretation due to dilution of gene transcripts derived from individual cell subsets or single cells which may be crucial for adaptive immune responses. To mitigate this drawback, analysis of purified cell subsets of interest is preferred, especially in the context of diseases that alter the distribution of specific cell subsets such as HIV infection ([@B24], [@B25]).

In the present study, we have applied basic principles of vaccinomics and systems biology, with the aim to dissect gene expression differences evident before vaccine administration between HIV-infected children under ART with stable virus control and their age matched healthy peers. Our analysis of B cell gene expression among HIV-infected children differentially responding to H1N1 revealed biologically meaningful predictive signatures of response to vaccination.

Materials and Methods {#S2}
=====================

Study Subjects and Design {#S2-1}
-------------------------

Twenty-three ART-treated HIV-1 vertically infected patients (HIV) and 10 healthy age-matched controls \[healthy controls (HCs)\] were enrolled at Bambino Gesù Children's hospital. Participant characteristics are shown in Table [1](#T1){ref-type="table"}. Written informed consent was obtained from all subjects or parents/guardians of all minors for participation in a prospective, open label influenza vaccine study (Figure [S1](#SM1){ref-type="supplementary-material"}A in Supplementary Material). Bambino Gesù Children's hospital ethics committee approved the study. Participants were immunized with a single dose of Inactivated Influenza Vaccine Trivalent Types A and B (Split Virion) VAXIGRIP^®^ (sanofi pasteur). The strains for the 2012--2013 season were A/California/7/2009 (H1N1) pdm09-like strain (abbreviated as H1N1), A/Victoria/361/2011 (H3N2)-like strain (abbreviated as H3N2), and B/Wisconsin/1/2010-like strain (abbreviated as B). Study design is outlined in Figure [S1](#SM1){ref-type="supplementary-material"}A in Supplementary Material. PBMCs, sera, and plasma were collected pre (T0) and 21 days postvaccination (T1) as previously described ([@B26], [@B27]). Among HIV, only patients with good adherence to ART and with history of long-term viral control (at least 24 months) were considered eligible for the study. No significant differences for ART type nor treatment duration were found between HIV Responders and HIV non-responders (NR, Table [1](#T1){ref-type="table"}).

###### 

Characteristics of study population.

  Baseline characteristics                               HIV NR            HIV R             HC
  ------------------------------------------------------ ----------------- ----------------- ---------------
  Age (years), mean (SEM)                                15.16 (2.1)       13.72 (2.3)       14.3 (3.3)
  *n* (female)                                           12 (7)            11 (5)            10 (5)
  %CD4^+^ T cells, mean (SEM)                            37.97 (4.9)       32.49 (6.0)       29.79 (6.2)
  HIV RNA \<50 cp/mL, *n*                                11                10                N/A
  IgG (mg/dL) (mean)                                     1,387.4           1,356             1,054.7
  IgM (mg/dL) (mean)                                     135.1             118.9             106.8
  IgA (mg/dL) (mean)                                     210.7             225.1             150
  CDC (A/B/C) (1/2/3)                                    (3/4/5) (3/4/5)   (2/5/4) (4/3/4)   N/A
  Lymphocytes/mm^3^, mean (SEM)                          2,494 (278.9)     3,109 (363.1)     3,063 (427.8)
  WBC (10^3^/μL), mean (SEM)                             7.6 (1.5)         7.3 (0.7)         7.9 (0.5)
  ART regimen (2 NRTI + PI/2 NRTI + nNRTI/2 NRTI + ii)   (5/5/2)           (5/4/2)           N/A

*CDC, Center for Disease Control classification of AIDS; WBC, white blood cells; ART, antiretroviral treatment; NRTI, nucleoside and nucleotide analog reverse transcriptase inhibitors; PI, protease inhibitors; nNRTI, non-nucleoside analog reverse transcriptase inhibitors; ii, integrase inhibitors*.

Hemagglutination Inhibition (HAI) Assay {#S2-2}
---------------------------------------

The HAI assay was performed and analyzed as previously described ([@B28]) (<http://www.gmp-compliance.org/guidemgr/files/021496EN.PDF>). The HAI antibody titers were expressed as the reciprocal of the highest serum dilution at which hemagglutination was prevented. Study participants were classified as vaccine responders (R) and vaccine NR according to the criteria established by Food and Drug Administration Guidance for Industry ([fda.gov](fda.gov)). R were characterized by HAI titer to H1N1 at T1 of ≥1:40 *and* ≥4-fold increase compared to baseline.

ELISpot {#S2-3}
-------

Peripheral blood mononuclear cells collected at T0 and T1 from HIV and HC were thawed and polyclonally activated *in vitro* in complete RPMI medium (Invitrogen) supplemented with 2.5 µg/mL CpG type B (Hycult biotech), 20 ng/mL IL-4 (Peprotech), and 20 ng/mL IL-21 (ProSpec). Cells were harvested after 5 days of culture at 37°C. ELISpot 96-well filtration plates (Millipore) were coated with purified H1N1 inactivated virus particles and subsequently loaded with 2 × 10^5^ cells/well. Plates were then processed as previously described ([@B2]). Response to H1N1 Ag was determined using the criteria ≥ or \<80 spots/10^6^ PBMCs in R and NR, respectively.

Cell Sorting, RNA Extraction and FACS Analysis {#S2-4}
----------------------------------------------

Cryopreserved PBMC from T0 and T1 were thawed, stained for the following previously titrated surface antibodies: CD10 (PECy7), CD20 (PE), CD27 (APC), IgD (FITC), CD21 (PECy5), and sorted by FACSAriaII (BD Biosciences). Vivid (Pacific Blue) was used to determine viability of cells. The gating strategy to identify B cell subsets, comprising total B cells (live, singlets, CD20^+^), total naive (IgD^+^CD27^−^), double negative (DN) (IgD^−^CD27^−^), RM (IgD^−^CD27^+^CD21^+^), and activated memory (AM) (IgD^−^CD27^+^CD21^−^) that were gated on the IgD^−^CD27^+^ class switched memory are shown in Figure [1](#F1){ref-type="fig"} and Figure [S1](#SM1){ref-type="supplementary-material"}B in Supplementary Material. IL-21 receptor on B cells has been analyzed as previously described ([@B11]). The purity of sorted cell populations was \>99%. Five hundred live cells per B cell subset were sorted with the sorting strategy depicted in Figure [S1](#SM1){ref-type="supplementary-material"}B in Supplementary Material in tubes previously loaded with 9 μL of CellsDirect one-step polymerase chain reaction (PCR) buffer and pooled TaqMan gene expression assays (2× CellsDirect Reaction mix 5 μL, Superscript III + Taq polymerase 0.5 μL, 0.2× TaqMan primer pool 2.5 μL, Resuspension Buffer 1 μL). After sorting, samples were transferred to PCR tubes and reverse transcription and target-specific preamplification was performed on a C1000 Thermal Cycler (BioRad) with the following scheme (50°C for 20 min, 95°C for 2 min, 95°C for 15 s, 60°C for 4 min, last two steps repeated for 18 cycles). Resulting cDNA was stored at −20°C until further analysis.

![B cell phenotype in HIV and age-matched healthy control (HC). Representative gates **(A)** and comparisons of B cell percentages **(B,C)**. Two tailed Mann--Whitney was used for comparisons. CD20^+^ cells established the B cell population, and expression of IgD, CD27, CD21, and CD10 was used to define total naive (CD27^−^IgD^+^), class switched CD27^+^ memory B cells (CD27^+^IgD^−^), double-negative (DN; CD27^−^IgD^−^), resting memory (RM), tissue-like (TL), activated memory (AM), and naive. FSC, forward scatter; SSC, side scatter. Contingency plot in **(C)** represents frequency of AM and RM in HIV and HC.](fimmu-08-01083-g001){#F1}

Multiplexed RT-PCR {#S2-5}
------------------

Previously amplified samples were loaded on a Fluidigm 96.96 standard chip following manufacturer's instructions. All primers/probes used for the gene mix are TaqMan gene expression assays (Table [S1](#SM9){ref-type="supplementary-material"} in Supplementary Material) and have been qualified on Human PBMCs and lymphocyte subsets following the method previously described ([@B29]). Gene selection was made according to previous analysis on Microarray of HIV-infected children (data not shown), literature, online gene banks, and biological queries. The sorting experiments and BioMark experiments were randomized to include a mix of HC, HIV, R, and NR patient samples so as not to bias the data toward one group by batch effects. Analysis was performed using Fluidigm Real-Time PCR Analysis software and "Multiple Chip Run" analysis mode. Cycle threshold values (Ct) were corrected according to the number of cells sorted if less than 500 according to the following calculation: *Y*/*X* = 67.5/500 (where *X* = actual number of cells sorted and *Y* = cDNA equivalent loaded onto BioMark chip). The dilution factor (*n*) was then calculated as *n* = 67.5/*Y* and log2(*n*) was subtracted from the Ct value to obtain Corrected Ct (cCt). Expression threshold (Et) values were calculated using the formula: Et = 40 − cCT, and Et was used for all downstream analysis. To verify consistency between individual BioMark runs, Et variance in B cells was calculated on the full set of genes. Housekeeping genes (*GAPDH, CD74*) included in our panel showed a low variation (\<0.1 score) across all samples in both PBMCs and sorted B cell subsets (not shown).

Enzyme-Linked Immunosorbent Assay (ELISA) {#S2-6}
-----------------------------------------

Plasma BAFF titers were measured as previously described ([@B30]). Briefly, plasma samples were diluted 1:1 and run in duplicate with 50 μL/well added to ELISA plates for human BAFF (R&D Systems).

Bioinformatics and Statistical Analysis {#S2-7}
---------------------------------------

Data were analyzed using Fluidigm SingulaR (SingulaR analysis toolset 3.0) package loaded on R (software R 3.0.2 GUI 1.62). We performed outlier identification analysis following manufacturer's instructions (Singular Analysis Toolset User Guide) on the whole dataset by cell subset and removed outliers from subsequent analysis. ANOVA was used to identify differentially expressed genes (DEGs), and interplay between cell subsets or patient groups was assessed through fold increase of the averages. Inter-individual differences and outliers were analyzed by SingulaR. The "mixOmics" package (Omics data integration project) for R was used as previously described ([@B31]). Pearson or Spearman correlation plots were generated with Prism 6.0 (GraphPad) after performing kolmogorov-smirnov normality test to determine distribution of the data. Statistical differences between postvaccination (T1) and prevaccination (T0) gene expression were determined by Wilcoxon matched paired test, and volcano plot was generated in Prism 6.0.

Results {#S3}
=======

Perturbed Gene Expression in Memory B Cells Persists in HIV-Infected Children Despite Effective ART and Normal B Cell Frequency {#S3-1}
-------------------------------------------------------------------------------------------------------------------------------

In order to characterize the B cell compartment of vertically HIV-infected children under ART and stable viral control, we assessed frequencies of total B cells and B cell subsets by flow cytometry. No differences in frequencies were found between HIV-infected and HC groups (Figures [1](#F1){ref-type="fig"}B,C).

To evaluate the B cell compartment at the transcriptional level, we performed multiplexed RT-PCR of a panel of 96 genes (Table [S1](#SM9){ref-type="supplementary-material"} in Supplementary Material) by Fluidigm Biomark™ in purified B cells from prevaccination samples. Principal component analysis (PCA) and hierarchical cluster analysis confirmed expected heterogeneity between memory subsets (AM and RM), and IgD^+^CD27^−^ (total naive) and DN subsets in HC and HIV (Figures [S2](#SM2){ref-type="supplementary-material"}A and [S3](#SM3){ref-type="supplementary-material"} in Supplementary Material). The greatest transcriptional variation was found between RM and the other three subsets in both HIV and HC participants, especially between RM and AM (77 DEGs in HIV and 23 DEGs in HC) marked by overall lower gene expression in RM (Figure [S2](#SM2){ref-type="supplementary-material"}B in Supplementary Material).

As shown in Figure [S2](#SM2){ref-type="supplementary-material"}B in Supplementary Material, all 23 DEGs identified by the comparison of RM to AM transcripts in HC are also present in HIV-infected individuals. To better understand the biological context of genes identified by differential expression analysis between RM and AM, we performed gene set enrichment analysis (GSEA) of preranked gene lists using published blood transcription modules as gene sets ([@B32]). These genes are mainly involved in regulation of lymphocyte activation and leukocyte proliferation (*CD28, PILRB, FOXO3, CD38, STAT5A, ABCB1, CD40L*), suggesting common intrinsic gene expression patterns characterizing AM in both HIV and HC. However, 54 additional DEGs were identified in the HIV-infected group when comparing gene transcripts present in RM and AM. These genes include additional immune activation and lymphocyte proliferation genes (*CD86, CAV1, CAMK4, TNFSF13, BTLA, MTOR*) as well as genes involved in the inflammatory response (*CYBB, NOD2, MYD88, IL10, CCR2*), type I Interferon signaling (*IFIT2, MX1, STAT1*) and response to virus (*APOBEC3G, BST2, TRIM 5*), all with significantly higher expression in AM compared to RM. Overall, the lower gene expression found in RM compared to AM may suggest that they are in a quiescent phase.

Next, we compared gene expression of each sorted B cell subset between HIV and HC to evaluate persistent defects in HIV infection despite viral control. Our results show that AM B cells clearly contrasted with 28 DEGs between HIV and HC (Figure [2](#F2){ref-type="fig"}A). Indeed, in this specific subset, already shown to dominate the HIV specific immune response in chronically infected adults ([@B24]), the DEGs showed higher expression in HIV compared to HC. Interestingly, this was not the case in PBMC and other sorted B cell subsets where few DEGs were identified in comparisons between HIV and HC: PBMC (5 DEGs), total B cells (0 DEGs), DN (2 DEGs), RM (2 DEGs), and total naive B cells (3 DEGs) (Figure [2](#F2){ref-type="fig"}A). GSEA analysis showed that genes expressed at higher levels in HIV compared to HC were mainly involved in inflammatory response and immune activation (*NOD2, IL2RA, SOCS1, IKBKG, CD69, CYBB, MYD88*) (Figure [2](#F2){ref-type="fig"}B; Figure [S4](#SM4){ref-type="supplementary-material"} in Supplementary Material). Enrichment of *NOD2* (fivefold) and *IL2RA* (fourfold) was found in AM from HIV compared to HC. *NOD2* is mainly involved in signal transduction and activation of nuclear factor kappa-B during inflammatory responses, and the *IL2RA* is part of the IL-2 receptor complex and is involved in activation and proliferation of the cell after an external stimulus. Other genes involved in response to HIV entry (*APOBEC3G, TRIM5*) and positive regulation of B cell-mediated immunity (*BTK, TNSF13*) were also higher in AM of HIV compared to HC, suggesting that underlying activation in this cell subset persists despite effective ART and long-term viral control.

![HIV present higher expression of genes involved in immuneactivation and inflammation in activated memory (AM) B cells despite effective antiretroviral therapy (ART) and long-term viral suppression. Graphs in panels **(A,B)** show comparisons in gene expression between healthy control (HC) and HIV. **(A)** Spider plot shows number of differentially expressed genes (DEGs) for all the subsets and total peripheral blood mononuclear cells (PBMCs). Box plots in panel **(B)** show gene expression averages from DEGS resulting in AM between HIV and HC (gene ranking defined by fold change). In this figure, *p*-values resulting from ANOVA analysis are shown. Color-labeled genes are defined according gene set enrichment analysis (performed by [genemania.org](genemania.org)) as described in the legend.](fimmu-08-01083-g002){#F2}

B Cell Gene Expression Profiles in HIV-Infected Children with Differing Response to H1N1 Vaccine Antigen {#S3-2}
--------------------------------------------------------------------------------------------------------

To determine how phenotype and transcriptional data associated with the ability of enrolled participants to respond to TIV, we applied two selection criteria (serology and Elispot) for separating study participants into responders (R) and NR (Figure [3](#F3){ref-type="fig"}A--C). The HIV-infected group contained approximately equal numbers of participants identified as R and NR, while all participants in the HC group were characterized as R. In agreement with our previous report ([@B4]), we found higher frequencies of IgD^−^CD27^−^ (DN) in NR compared to HC (Figure [S5](#SM5){ref-type="supplementary-material"}A in Supplementary Material). We also observed similar frequencies of class switched CD27^+^ memory B cells (CD19^+^CD27^+^IgD^−^) among the groups (HC, NR, and R) (Figure [S5](#SM5){ref-type="supplementary-material"}A in Supplementary Material); however, AM were significantly higher in NR compared to both R and HC (Figure [S5](#SM5){ref-type="supplementary-material"}B in Supplementary Material).

![H1N1 response after trivalent inactivated influenza in HIV and perturbation of the memory compartment among non-responders. **(A)** The flow chart describes the criteria of selection used to define responders and non-responders to trivalent-inactivated influenza vaccination (TIV) among HIV-infected children. As a first criteria of selection, all patients were selected according to the fold increase of H1N1 hemagglutination inhibition (HAI) titer. Patients responding or not responding to the first selection criteria were further selected according to H1N1 ELISpot response. Selected healthy donors responded to the vaccination and met both criteria of selection. Representative ELISpot assay **(B)** and scatter dot plot **(C)** show ELISpot data for H1N1.](fimmu-08-01083-g003){#F3}

At a transcriptional level, intersubset analysis comparing AM and RM revealed fewer DEGs in R than NR due to overall higher gene expression in the RM subset from R (Figure [S6](#SM6){ref-type="supplementary-material"}A in Supplementary Material). We further noted that although most of the DEGs in the total HIV group were present in the comparison between NR and HC (47 DEGs) (Figure [S6](#SM6){ref-type="supplementary-material"}A and Table [S2](#SM10){ref-type="supplementary-material"} in Supplementary Material), only 20 additional DEGs were identified between HIV R and HC (AM vs. RM).

Next, we performed GSEA on DEGs within AM from comparisons between HIV-infected participants (both R and NR separately) and HC. This analysis showed enriched pathways in positive regulation of apoptotic process (*FAS, BAX, PILRB*), B cell activation, and Fc receptor signaling (*BATF, FYN, PLCG1, CD27, CD28*) in HIV (Figures [S6](#SM6){ref-type="supplementary-material"}B,C and Table [S3](#SM11){ref-type="supplementary-material"} in Supplementary Material). Collectively, gene expression data from AM B cells demonstrate that this subset, which has been shown to accumulate in individuals with HIV infection ([@B14], [@B33]), displays a distinct transcription profile compared to HC independent of TIV response.

Distinct Prevaccination Gene Expression Patterns in RM from HIV-Infected Children Responding to H1N1 {#S3-3}
----------------------------------------------------------------------------------------------------

Our analysis of RM identified 25 genes that were differentially expressed between NR and R in HIV participants prior to vaccination with TIV (Figure [4](#F4){ref-type="fig"}A). RM from NR exhibited overall lower gene expression compared to HC and R. DEGs from this analysis, which were expressed higher in R, are directly involved in regulation of the adaptive immune response through somatic recombination from the immunoglobulin superfamily domain \[*TNFSF13*(APRIL), *BTK*\], leukocyte activation and BCR signaling pathways (*MTOR, FYN, CD86*). As shown in Figure [4](#F4){ref-type="fig"}B, genes involved in the *JAK/STAT* signaling cascade (*STAT4, IL6R, IFNAR*) and the closely related type I interferon response (*IFNAR2, MX1*) were higher in R. In addition, *PRDM1* (BLIMP1), able to induce B cell differentiation into plasma cells after encountering Ag ([@B34]), was higher in RM of R compared to NR. Collectively, these results show that the RM B cell subset, crucial for potent and specific adaptive immune responses, exhibits a distinct prevaccination transcriptional profile in HIV-infected participants who will mount an effective response to H1N1.

![Prevaccination gene signatures in RM B cell subset discriminate HIV-infected R and non-responder (NR). **(A)** Spider plot shows number of differentially expressed genes (DEGs) for all the subsets and total peripheral blood mononuclear cells (PBMCs). **(B)** Heatmap shows gene expression in R and NR. Colored genes' names refer to gene set enrichment analysis (GSEA) legend. In panels **(C,D)**, correlation between gene expression in resting memory and H1N1-seroconversion **(C)** and ELISpot at T1 **(D)** are shown. *p* and *r* values show results from correlation analyses (Pearson or Spearman tests for parametric and non-parametric data, respectively).](fimmu-08-01083-g004){#F4}

The gene set found to be different between NR and R was further analyzed for differences between pre vaccination (T0) and post vaccination (T1) gene expression in RM. Paired analysis revealed that *PRDM1* (BLIMP1) was significantly reduced at T1 when compared to T0 in HIV (*p* = 0.0039, median difference = −7.52) (Figure [S7](#SM7){ref-type="supplementary-material"}A in Supplementary Material). This longitudinal reduction was strongly confirmed in R with all R showing a reduction of *PRDM1* at T1 (*p* = 0.0001, median difference = −8.9), whereas significance was lost when only NR were taken into account (Figure [S7](#SM7){ref-type="supplementary-material"}B in Supplementary Material).

To further dissect the relationship of clinical (i.e., serological) markers of response to H1N1 and gene expression patterns, we performed pairwise correlation analysis using the two datasets. We confirmed the findings from differential gene expression analysis of prevaccination RM and found a positive correlation of *BTK* expression in RM at T0 and H1N1 seroconversion (HAI H1N1 Titer T1/T0) (Figure [4](#F4){ref-type="fig"}C) and H1N1 ELIspot at T1 (Figure [4](#F4){ref-type="fig"}D). Additional genes actively involved in proliferation and lymphocyte activation correlated with vaccine response in terms of H1N1 seroconversion (*CD69, CD86*) and H1N1 ELISpot at T1 (*CD69*). Interestingly, genes involved in inhibition of the apoptotic process (*LIGHT, BCL2*) showed positive correlations with H1N1 ELISpot at T1. Overall, these results demonstrate that the memory B cell compartment is highly impacted by HIV infection and suggest that an activated profile of specific genes in RM is required to maintain a normal adaptive response in HIV-infected patients.

We further asked whether gene expression analysis was correlated to measurements of plasma biomarkers or cell surface molecule expression encoded by the corresponding genes. To do so, we correlated gene expression data with plasma levels of BAFF (B cell activating factor) and with IL-21R^+^ B cell frequency, two molecules already shown to be involved in the immune response against H1N1 after vaccination ([@B4], [@B30]). Interestingly, *TNFSF13B* (BAFF) gene expression in RM was positively correlated with plasma BAFF levels at the time of vaccination (Figures [S8](#SM8){ref-type="supplementary-material"}A,C in Supplementary Material). Further, gene expression of *IL21R* in sorted RM was positively correlated with the expression of IL-21R as analyzed by flow cytometry (Figures [S8](#SM8){ref-type="supplementary-material"}B,D in Supplementary Material). These data show that transcriptional data may provide a functional correlate in specific molecules involved in the B cell memory response and maintenance over time.

Discussion {#S4}
==========

This study represents the first evaluation of gene expression patterns in B cell subsets, total B cells and PBMCs in the field of pediatric HIV infection and in the context of immune responses to H1N1 antigen post-TIV. In the field of vaccinomics, systems biology tools have lately generated exciting data revealing molecular mechanisms of immunity induced by vaccination and correlates of protection in order to predict the vaccine efficacy in healthy adults ([@B35], [@B36]). However, as recently shown, the influence of age on gene expression patterns should be taken into account when interpreting systems biology data ([@B37]). Additionally, gene signatures identified in healthy adults and in the heterogeneous pool of PBMCs ([@B38], [@B39]) are not directly applicable to pediatric studies ([@B40]), and most likely not even in patients affected by chronic conditions such as HIV infection ([@B41]). Therefore, we believe that gene expression patterns identified in specific cell subsets may be crucial to investigate the dynamic of vaccine response in HIV-infected children.

In the present study, the analysis of gene expression from purified B cell subsets showed that perturbations in memory B cells persist in HIV-infected children despite stable and long-term virological control. Our results suggest that in these patients, the recovery achieved in overall B cell frequencies is not accompanied by recovery of gene expression and B cell function. We identified clear-cut differences in gene signatures between AM B cells of HIV-infected children and their healthy peers. B cell subsets between study groups were skewed in AM of HIV-infected children toward hyperexpression of genes involved in immune exhaustion/inflammation (*CYBB, MYD88, NOD2, IL2RA*) and apoptosis (*SOCS1, RUNX3*). The immune activation and exhaustion pattern, hereby confirmed at a transcriptional level in this particular subset of B cells, may play a key role in the "inflamm-aging" process which leaves ART-treated HIV-infected patients vulnerable to increased risk of non-AIDS defining comorbidities such as malignancies and cardiovascular diseases ([@B42], [@B43]). Indeed, despite the advent of ART which has dramatically increased life expectancy, non-AIDS defining malignancies are still increasing in ART-treated and virologically controlled HIV-infected children ([@B44]--[@B46]). The AM B cell subset was previously described to be enriched in HIV ([@B47]), to be prone to functional "exhaustion," and to dominate HIV-specific responses ([@B24]). Furthermore, it has been recently reported in adults that signs of chronic inflammation persist over time even when treatment is started during acute infection ([@B48]). It is still unknown whether antiretroviral regimens may differentially impact B cell gene transcriptional patterns. Although in the present study, no differences in terms of ART regimen were found between the study groups (responders and not responders), these specific effects should be addressed in future investigations and in larger cohorts. Other differences between ART-treated HIV and uninfected children have emerged through comparison of B cell subsets within participant groups (see Figure [S2](#SM2){ref-type="supplementary-material"}B in Supplementary Material). However, we believe that transcriptional analysis of rare and still biologically ill-expanded cell subsets, such as DN and AM ([@B47], [@B49]), would benefit more from an unbiased whole transcriptome approach (e.g., RNA Seq) on sorted subsets and after *in vitro* or *in vivo* stimulation in order to provide more definitive results.

Despite this limitation, in line with our previous report ([@B27]) and together with findings reported herein, the perturbation of the AM subset may underlie mechanisms of premature aging of the immune system and impaired ability of HIV-infected patients to respond to vaccinations and to maintain a long-term immune response ([@B50]).

Although limited by the small sample size, gene expression data from RM B cells, revealed a 25 gene signature that distinguished responders and NR to H1N1. Interestingly, these data were derived from samples collected *before* vaccination. This observation may suggest that in the context of HIV infection, RM B cells, which provide secondary, potent and specific immune responses ([@B51]) need to present a specific gene expression pattern in order to provide an effective response to vaccination. Most of the genes involved in the signature are directly involved in the B cell receptor gene signaling cascade and in B cell development (*APRIL, BTK, PI3K, MTOR, BST2*), suggesting that a lower expression of these genes may contribute to a reduced Ab production upon Ag-recall responses. These results are in line with recent data suggesting that modules of genes related to B cell and plasmablasts may be crucial indicators and biomarkers of vaccine induced immunogenicity and protection ([@B21]). Although our study was mainly focused on prevaccination signature of response in HIV-infected patients, we performed longitudinal analysis to investigate differences in gene expression of RM from samples collected at 21 days after vaccination (T1) compared to baseline (T0). Expression of *PRDM1* (BLIMP1), a transcriptional repressor that drives terminal differentiation into plasma cells was found higher in RM of HIV responders at baseline and was significantly reduced at T1 when compared to T0 in HIV and particularly in R (Figure [S7](#SM7){ref-type="supplementary-material"} in Supplementary Material). Reduction of *PRDM1* may represent the resting phase of Ag specific B cells after migration to the germinal centers, class switch recombination, and somatic hypermutation ([@B34], [@B52]). Another consideration is that earlier timepoints (24 h to 1 week) after immunization or after re-exposure to the Ag will need to be tested in order to confirm this hypothesis and define the genes' activation programs which orchestrate memory B cell responses in HIV-infected children. Indeed in recent studies early changes of genes enriched in B cells, plasmablasts and immunoglobulins after administration of the RTS,S/AS01 malaria vaccine in healthy malaria-naive adults, were found to be related to vaccine Ab production and cell-related immunogenicity ([@B19]).

Our data on RM transcriptional signatures revealed that H1N1 responders expressed higher JAK-STAT cascade genes (*MX1, IFNAR, STAT4*). These findings are consistent with previous reports showing that STAT genes are crucial in the differentiation of RM B cells induced by IL-21 ([@B53]). In this context and following a similar experimental approach as this, we recently reported that *IL21* gene expression from prevaccination purified peripheral T follicular helper cells (pTfh) after *in vitro* stimulation, is an indicator of vaccine response ([@B54]).

The present study identified predictive correlates of seroconversion following immunization using pair-wise correlation analysis between individual gene expression data and serological data. In RM, *BTK*, involved in B cell development, and *CD86*, a lymphocyte activation gene, showed significant positive correlations with H1N1 seroconversion after vaccination in HIV supporting the hypothesis that gene signatures in purified RM B cells at the time of immunization may predict the ability of HIV-infected children to respond to vaccinations. Taken together these findings suggest that specific gene signatures in cell subsets directly involved in Ab production and response to Ag (pTfh and RM B cells) are needed to provide an efficient immune response and are altered in HIV infection.

This experimental approach, based on a targeted gene selection (*n* = 96) rather than unbiased whole transcriptome sequencing, illustrates the benefits of analysis of purified cell subsets. The increased specificity resulting from this approach is important, considering the observed phenotypic alterations in immune cells from HIV-infected patients. We believe that these data provide a strong rationale to warrant future larger studies that can expand and validate these findings.
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###### 

Experimental design. Cartoon in panel **(A)** depicts design of the study. Peripheral blood mononuclear cells (PBMCs) were collected at the time of vaccination (T0) and 21 days after vaccination (T1). At both timepoints, hemagglutination inhibition assay (HIA), and H1N1 ELISpot were performed. Briefly, in panel **(B)** PBMCs stored in liquid nitrogen were thawed and stained for surface molecules and analyzed by flow cytometry (ARIA II cs). Equal number (500 cells) of cells from 5 subsets and total PBMCs from unstimulated samples were sorted as depicted in the sorting strategy into tubes previously coated with specific polymerase chain reaction (PCR) buffer. Data, collected through Fluidigm Real Time PCR analysis software was then analyzed through Fluidigm SingulaR (SingulaR analysis toolset 3.0) package, loaded on R (software R 3.0.2 GUI 1.62). Data were later used for mixOmics on R (mixOmics package) and for gene set enrichment analysis (GSEA).

###### 

Click here for additional data file.

###### 

Gene expression patterns of memory B cell subsets rather than B cell frequencies differentiates virally controlled HIV-infected children from their healthy peers. **(A)** Principal component analysis (PCA) shows segregation among the four different B cell subsets in healthy controls (HC) and HIV. JMP©, SAS^®^ has been used to produce the PCA. **(B)** Venn diagram shows differentially expressed genes (DEGs) found when gene expression of activated memory (AM) and resting memory (RM) are compared between HIV and HC. Only ANOVA analyses with a *p* value \< 0.05 are shown. Genes marked with the asterisk show *p* values ≤ 0.01. All 23 DEGs found in HC were overlapping in HIV (light gray box). 54 additional DEGs were found in HIV only (dark gray box).
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Click here for additional data file.

###### 

Differential inter subset analysis. Heatmap of intersubset analysis in healthy controls (HC) **(A)** HIV **(B)**, R **(C)**, and NR **(D)**. Heatmap analyses were generated by singular analysis toolset after identification and removal of outliers.

###### 

Click here for additional data file.

###### 

Gene set enrichment analysis from differentially expressed genes resulting from activated memory in HIV vs. healthy controls (HC). Gene Set Enrichment Analysis in the graph was generated by genemania cytoscape app ([genemania.org](genemania.org)).
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Click here for additional data file.

###### 

Scatter dot plot in panel (A) shows frequencies of total B cells (live, CD10^−^, CD20^+^); and among B cells: double negative (CD27^−^, IgD^−^), total naive (CD27^−^, IgD^+^), class switched CD27^+^ memory B cells (CD27^+^, IgD^−^), tissue like (CD27^−^, IgD^−^, CD21^−^). In panel **(B)** activated memory (CD27^+^, IgD^−^, CD21^−^) and resting memory (CD27^+^, IgD^−^, CD21^+^) (two tailed Mann--Whitney test for comparisons) are shown.
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Click here for additional data file.

###### 

Activated memory (AM) vs. resting memory (RM) differentially expressed genes (DEGs) in healthy controls (HC), R and NR. Venn Diagram in panel (A) shows DEGs found when gene expression of AM and RM are compared between HIV R, HIV NR, and HC. Only ANOVA analysis with a *p* value \< 0.05 are shown. **(B,C)** gene set enrichment analysis of DEGs derived from activated memory vs. resting memory of HIV NR vs. HC **(B)** and HIV R vs. HC **(C)** are shown.
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Click here for additional data file.

###### 

Post vaccination (T1) *PRDM1* (*BLIMP1*) gene expression is reduced in resting memory (RM) of HIV-infected children compared to baseline (T0). In panel **(A)**, volcano plot shows differences in gene expression between T1 and T0 in selected genes from sorted RM. In panel **(B)** paired analysis in R (green) and NR (red) of PRDM1 are shown. *P*-Values and median differences derive from Wilcoxon paired t test performed by graphpad (prism 6.0).
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Click here for additional data file.

###### 

IL21R and BAFF (*TNFSF13B*) gene expression in resting memory (RM) correlates with surface molecules and plasma levels. In panel **(A)** heatmap analysis shows *r* values resulting from pairwise Spearman correlations between the aforementioned observations. In **panels (B--D)**, correlation dot plots of the afore mentioned analysis are shown. In the graph gene expression resulting from RM is shown.
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Click here for additional data file.
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The full list of genes, alias names and assay codes used for multiplexed principal component analysis are shown in the table.
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Click here for additional data file.

###### 

Differentially expressed genes (DEGs) between cell subsets in HIV, healthy controls (HC), R and NR. Table shows DEGs in all groups (HIV, HC, HIV NR, HIV R) when subsets were compared. In the table, cells are highlighted in orange when *p* values were \<0.01 and not highlighted when *p* value \<0.05. Outlined cells define an opposite relation compared to the one in the headline.
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Click here for additional data file.

###### 

Differentially expressed genes between study groups. Note: *[genemania.org](genemania.org) gene set enrichment analysis (GSEA)* In every graph presented throughout the paper, circles with diagonal lines define genes included in the GSEA. Its function is described legend below the graph. The solid circles represent genes resulted to be involved in the pathways. Networks among the genes are defined by colored lines, further explained by legends.
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Click here for additional data file.
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